论文部分内容阅读
移植排斥是异体 /种组织和器官移植中长期存在而尚未克服的医学难题。目前临床应用的免疫抑制剂虽能使移植排斥反应得到有效控制 ,但由于其对受者免疫系统非选择性的广泛抑制而常引起感染、肿瘤发生等诸多并发症。因此诱导供者特异性免疫耐受被认为是最终克服移植排斥的有效途径。树突状细胞 (dendriticcell,DC)由于来源、发育阶段不同而存在的功能异质性 ,使其成为诱导移植免疫耐受的重要靶细胞
Transplant rejection is a longstanding medical problem that has not been overcome in allogeneic tissue and organ transplantation. Although currently used in clinical immunosuppressive agents can effectively control graft rejection, but due to its extensive non-selective inhibition of the immune system and often caused by infection, tumor and many other complications. Therefore, induction of donor-specific immune tolerance is considered as an effective way to eventually overcome graft rejection. The functional heterogeneity of dendritic cells (DCs) due to different origins and stages of development makes them important target cells for inducing immune tolerance in transplantation